28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy

PurposeCoumadin identified by Institute for Safe Medication Practice as high–risk medication with narrow therapeutic window and high risk of life threatening adverse effectsAnticoagulants identified as one of the top five drug types associated with patient safety incidentsMaintaining INR in recommen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Heart (British Cardiac Society) 2018-02, Vol.104 (Suppl 2), p.A10
Hauptverfasser: Jedeikin, R, Rutt, K, Trujillo, S, Preston, T, Olson, S
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page A10
container_title Heart (British Cardiac Society)
container_volume 104
creator Jedeikin, R
Rutt, K
Trujillo, S
Preston, T
Olson, S
description PurposeCoumadin identified by Institute for Safe Medication Practice as high–risk medication with narrow therapeutic window and high risk of life threatening adverse effectsAnticoagulants identified as one of the top five drug types associated with patient safety incidentsMaintaining INR in recommended therapeutic ranges reducing the incidence of adverse effectsImprove INR–TTR(time in therapeutic range) in patients managed through the Coumadin ClinicComply with nationally established INR goal guidelinesMethodsDevelop routine order setsDefine team roles/expectationsDevelop point–of–care resource optimising access to INR testing.Educational program targeting stakeholdersMonthly meeting auditing patients with goal analysis utilising tracking toolsReview of process/outcome measures.Intervene for change utilising PDSA methodologyPDSA Cycle 1:Retrospective data collection–2008No systematic approach in place/data regarding patient TTR not availableNo structured staff/patient education programPDSA Cycle 2:Implement changesWeb–based software purchasedStructured approach to INR management implemented including stakeholder education programPDSA Cycle 3:Problem monitoring/notifying overdue INR patientsTeam member roles/responsibilities redefined‘Buddy system’ implemented to monitor/notify overdue patientsResultsTTR increased from 66%-2008 to 79%-2013 following implementation of structured policies/programsRe–implementation of education program, revision of policy/procedures TTR increased to 80% Jan–May–2015Optimized point–of–care for INR testing–office finger–stick/remote laboratory testing/home monitoringIncreased INR home monitoringConclusionWith development of systematic approach to high risk patients on anticoagulation therapy, using a web–based software program, significant changes were evident:Improved patient follow–up, communication, decrease in overdue patient numbersIncreased percentage of patients’ within INR rangeApproach driven by the PDSA CQI methodology
doi_str_mv 10.1136/heartjnl-2017-BCCA.28
format Article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_1993540140</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993540140</sourcerecordid><originalsourceid>FETCH-LOGICAL-b690-c99311b6f7eb16af8402da79a7c50baee57ccd282d9c5125b967e239c14d36613</originalsourceid><addsrcrecordid>eNo1kM1OhDAUhRujiePoI5g0cc3YHyh0OY6_iYmbWbhrLqUICBTbos7OjS_qkwgZXd2Tm3POzf0QOqdkRSkXl5UBF5q-jRihaXS12axXLDtACxqLbN49H06aJ0kkCE-P0Yn3DSEklplYoE-W_Xx9X5t309qhM33AtsSA_c4H00GoNYZhcBZ0hYPFzhSjNjhUBrf1q2nrytpiTgyTdQ5X4DoM3ltdQzAF_qhDhaGfeiy8jO2k5rCDYXeKjkpovTn7m0u0vb3Zbu6jx6e7h836McqFJJGWklOaizI1ORVQZjFhBaQSUp2QHIxJUq0LlrFC6oSyJJciNYxLTeOCC0H5El3sa6cn3kbjg2rs6PrpoqJTdxITGpPJRfauvGvU4OoO3E5Roma86h-vmvGqGa9iGf8FawpzXA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1993540140</pqid></control><display><type>article</type><title>28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy</title><source>PubMed Central</source><creator>Jedeikin, R ; Rutt, K ; Trujillo, S ; Preston, T ; Olson, S</creator><creatorcontrib>Jedeikin, R ; Rutt, K ; Trujillo, S ; Preston, T ; Olson, S</creatorcontrib><description>PurposeCoumadin identified by Institute for Safe Medication Practice as high–risk medication with narrow therapeutic window and high risk of life threatening adverse effectsAnticoagulants identified as one of the top five drug types associated with patient safety incidentsMaintaining INR in recommended therapeutic ranges reducing the incidence of adverse effectsImprove INR–TTR(time in therapeutic range) in patients managed through the Coumadin ClinicComply with nationally established INR goal guidelinesMethodsDevelop routine order setsDefine team roles/expectationsDevelop point–of–care resource optimising access to INR testing.Educational program targeting stakeholdersMonthly meeting auditing patients with goal analysis utilising tracking toolsReview of process/outcome measures.Intervene for change utilising PDSA methodologyPDSA Cycle 1:Retrospective data collection–2008No systematic approach in place/data regarding patient TTR not availableNo structured staff/patient education programPDSA Cycle 2:Implement changesWeb–based software purchasedStructured approach to INR management implemented including stakeholder education programPDSA Cycle 3:Problem monitoring/notifying overdue INR patientsTeam member roles/responsibilities redefined‘Buddy system’ implemented to monitor/notify overdue patientsResultsTTR increased from 66%-2008 to 79%-2013 following implementation of structured policies/programsRe–implementation of education program, revision of policy/procedures TTR increased to 80% Jan–May–2015Optimized point–of–care for INR testing–office finger–stick/remote laboratory testing/home monitoringIncreased INR home monitoringConclusionWith development of systematic approach to high risk patients on anticoagulation therapy, using a web–based software program, significant changes were evident:Improved patient follow–up, communication, decrease in overdue patient numbersIncreased percentage of patients’ within INR rangeApproach driven by the PDSA CQI methodology</description><identifier>ISSN: 1355-6037</identifier><identifier>EISSN: 1468-201X</identifier><identifier>DOI: 10.1136/heartjnl-2017-BCCA.28</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Anticoagulants ; Education ; Patients ; Software</subject><ispartof>Heart (British Cardiac Society), 2018-02, Vol.104 (Suppl 2), p.A10</ispartof><rights>2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids></links><search><creatorcontrib>Jedeikin, R</creatorcontrib><creatorcontrib>Rutt, K</creatorcontrib><creatorcontrib>Trujillo, S</creatorcontrib><creatorcontrib>Preston, T</creatorcontrib><creatorcontrib>Olson, S</creatorcontrib><title>28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy</title><title>Heart (British Cardiac Society)</title><description>PurposeCoumadin identified by Institute for Safe Medication Practice as high–risk medication with narrow therapeutic window and high risk of life threatening adverse effectsAnticoagulants identified as one of the top five drug types associated with patient safety incidentsMaintaining INR in recommended therapeutic ranges reducing the incidence of adverse effectsImprove INR–TTR(time in therapeutic range) in patients managed through the Coumadin ClinicComply with nationally established INR goal guidelinesMethodsDevelop routine order setsDefine team roles/expectationsDevelop point–of–care resource optimising access to INR testing.Educational program targeting stakeholdersMonthly meeting auditing patients with goal analysis utilising tracking toolsReview of process/outcome measures.Intervene for change utilising PDSA methodologyPDSA Cycle 1:Retrospective data collection–2008No systematic approach in place/data regarding patient TTR not availableNo structured staff/patient education programPDSA Cycle 2:Implement changesWeb–based software purchasedStructured approach to INR management implemented including stakeholder education programPDSA Cycle 3:Problem monitoring/notifying overdue INR patientsTeam member roles/responsibilities redefined‘Buddy system’ implemented to monitor/notify overdue patientsResultsTTR increased from 66%-2008 to 79%-2013 following implementation of structured policies/programsRe–implementation of education program, revision of policy/procedures TTR increased to 80% Jan–May–2015Optimized point–of–care for INR testing–office finger–stick/remote laboratory testing/home monitoringIncreased INR home monitoringConclusionWith development of systematic approach to high risk patients on anticoagulation therapy, using a web–based software program, significant changes were evident:Improved patient follow–up, communication, decrease in overdue patient numbersIncreased percentage of patients’ within INR rangeApproach driven by the PDSA CQI methodology</description><subject>Anticoagulants</subject><subject>Education</subject><subject>Patients</subject><subject>Software</subject><issn>1355-6037</issn><issn>1468-201X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNo1kM1OhDAUhRujiePoI5g0cc3YHyh0OY6_iYmbWbhrLqUICBTbos7OjS_qkwgZXd2Tm3POzf0QOqdkRSkXl5UBF5q-jRihaXS12axXLDtACxqLbN49H06aJ0kkCE-P0Yn3DSEklplYoE-W_Xx9X5t309qhM33AtsSA_c4H00GoNYZhcBZ0hYPFzhSjNjhUBrf1q2nrytpiTgyTdQ5X4DoM3ltdQzAF_qhDhaGfeiy8jO2k5rCDYXeKjkpovTn7m0u0vb3Zbu6jx6e7h836McqFJJGWklOaizI1ORVQZjFhBaQSUp2QHIxJUq0LlrFC6oSyJJciNYxLTeOCC0H5El3sa6cn3kbjg2rs6PrpoqJTdxITGpPJRfauvGvU4OoO3E5Roma86h-vmvGqGa9iGf8FawpzXA</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Jedeikin, R</creator><creator>Rutt, K</creator><creator>Trujillo, S</creator><creator>Preston, T</creator><creator>Olson, S</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201802</creationdate><title>28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy</title><author>Jedeikin, R ; Rutt, K ; Trujillo, S ; Preston, T ; Olson, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b690-c99311b6f7eb16af8402da79a7c50baee57ccd282d9c5125b967e239c14d36613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Anticoagulants</topic><topic>Education</topic><topic>Patients</topic><topic>Software</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jedeikin, R</creatorcontrib><creatorcontrib>Rutt, K</creatorcontrib><creatorcontrib>Trujillo, S</creatorcontrib><creatorcontrib>Preston, T</creatorcontrib><creatorcontrib>Olson, S</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Heart (British Cardiac Society)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jedeikin, R</au><au>Rutt, K</au><au>Trujillo, S</au><au>Preston, T</au><au>Olson, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy</atitle><jtitle>Heart (British Cardiac Society)</jtitle><date>2018-02</date><risdate>2018</risdate><volume>104</volume><issue>Suppl 2</issue><spage>A10</spage><pages>A10-</pages><issn>1355-6037</issn><eissn>1468-201X</eissn><abstract>PurposeCoumadin identified by Institute for Safe Medication Practice as high–risk medication with narrow therapeutic window and high risk of life threatening adverse effectsAnticoagulants identified as one of the top five drug types associated with patient safety incidentsMaintaining INR in recommended therapeutic ranges reducing the incidence of adverse effectsImprove INR–TTR(time in therapeutic range) in patients managed through the Coumadin ClinicComply with nationally established INR goal guidelinesMethodsDevelop routine order setsDefine team roles/expectationsDevelop point–of–care resource optimising access to INR testing.Educational program targeting stakeholdersMonthly meeting auditing patients with goal analysis utilising tracking toolsReview of process/outcome measures.Intervene for change utilising PDSA methodologyPDSA Cycle 1:Retrospective data collection–2008No systematic approach in place/data regarding patient TTR not availableNo structured staff/patient education programPDSA Cycle 2:Implement changesWeb–based software purchasedStructured approach to INR management implemented including stakeholder education programPDSA Cycle 3:Problem monitoring/notifying overdue INR patientsTeam member roles/responsibilities redefined‘Buddy system’ implemented to monitor/notify overdue patientsResultsTTR increased from 66%-2008 to 79%-2013 following implementation of structured policies/programsRe–implementation of education program, revision of policy/procedures TTR increased to 80% Jan–May–2015Optimized point–of–care for INR testing–office finger–stick/remote laboratory testing/home monitoringIncreased INR home monitoringConclusionWith development of systematic approach to high risk patients on anticoagulation therapy, using a web–based software program, significant changes were evident:Improved patient follow–up, communication, decrease in overdue patient numbersIncreased percentage of patients’ within INR rangeApproach driven by the PDSA CQI methodology</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/heartjnl-2017-BCCA.28</doi></addata></record>
fulltext fulltext
identifier ISSN: 1355-6037
ispartof Heart (British Cardiac Society), 2018-02, Vol.104 (Suppl 2), p.A10
issn 1355-6037
1468-201X
language eng
recordid cdi_proquest_journals_1993540140
source PubMed Central
subjects Anticoagulants
Education
Patients
Software
title 28 Development of a systematic approach to reduce the likelihood of patient harm associated with anticoagulant therapy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T03%3A27%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=28%E2%80%85Development%20of%20a%20systematic%20approach%20to%20reduce%20the%20likelihood%20of%20patient%20harm%20associated%20with%20anticoagulant%20therapy&rft.jtitle=Heart%20(British%20Cardiac%20Society)&rft.au=Jedeikin,%20R&rft.date=2018-02&rft.volume=104&rft.issue=Suppl%202&rft.spage=A10&rft.pages=A10-&rft.issn=1355-6037&rft.eissn=1468-201X&rft_id=info:doi/10.1136/heartjnl-2017-BCCA.28&rft_dat=%3Cproquest_bmj_p%3E1993540140%3C/proquest_bmj_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1993540140&rft_id=info:pmid/&rfr_iscdi=true